Business
Alumis is a clinical-stage biopharmaceutical company developing targeted immunology therapies, with envu, formerly ESK-001, and A-005 as TYK2 inhibitor programs.
Alumis generated $24.1M of collaboration revenue, but free cash flow worsened to -$370.2M.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage TYK2 immunology pipelineWatch
- Revenue — $24.1M collaboration revenueNote
- Profitability — Operating loss was $453.8MWatch
- Cash — Free cash flow was -$370.2MWatch
- Insiders — Cluster buy: $42.8M boughtOK
- Balance sheet — Equity rose to $301.3MOK
- Accounting — Altman-Z distress; other scores unavailableWatch
Where the revenue comes from
Fiscal 2025, as ALUMIS INC. reports it. History and quarterly detail are in the app.
- License$17.4M
- Collaboration Revenue$6.7M
Leadership changes
From ALUMIS INC.'s own filings, the day they're filed.
- Eligible Employees · departure
- Covered Termination · departure
- Control Period If · departure
Latest filings
- 8-K · Company announcement2026-09-01
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ALUMIS INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.